The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

The present disclosure relates to a method for immobilizing heparin and a NO-generating catalyst and a cardiovascular device having a surface modified using the same, and more particularly, to a method of co-immobilizing a heparin-phenol derivative and copper nanoparticles as a NO-generating catalyst on the surface of a material by a polyphenol oxidase-mediated reaction, a material having a surface with heparin and a NO-generating catalyst co-immobilized thereon by using the method, and a cardiovascular device including the material. It has been confirmed that a surface having heparin and the NO-generating catalyst co-immobilized thereon by the method of the present disclosure has high in vivo stability, continuously generates NO, and also promotes the proliferation of endothelial cells while significantly inhibiting the adhesion and activation of platelets and smooth muscle cells. Thus, the method may be advantageously applied to cardiovascular devices for inhibiting thrombosis and restenosis.

The present disclosure relates to a method for immobilizing heparin and a NO-generating catalyst and a cardiovascular device having a surface modified using the same, and more particularly, to a method of co-immobilizing a heparin-phenol derivative and copper nanoparticles as a NO-generating catalyst on the surface of a material by a polyphenol oxidase-mediated reaction, a material having a surface with heparin and a NO-generating catalyst co-immobilized thereon by using the method, and a cardiovascular device including the material. It has been confirmed that a surface having heparin and the NO-generating catalyst co-immobilized thereon by the method of the present disclosure has high in vivo stability, continuously generates NO, and also promotes the proliferation of endothelial cells while significantly inhibiting the adhesion and activation of platelets and smooth muscle cells. Thus, the method may be advantageously applied to cardiovascular devices for inhibiting thrombosis and restenosis.

A method for preparing a hydrogel comprising mixing a solution of a polymer with a photoinitiator, where the polymer comprises multiple subunits each having a non-aromatic unsaturated functional group, and irradiating the mixture with visible light to produce the hydrogel.

A method for preparing a hydrogel comprising mixing a solution of a polymer with a photoinitiator, where the polymer comprises multiple subunits each having a non-aromatic unsaturated functional group, and irradiating the mixture with visible light to produce the hydrogel.

A method of manufacturing a medical product having an engineered heparin bioactive matrix for clinical application on a blood contacting surface comprises: a) activating a blood contacting surface of at least one component of a medical device via one of plasma treatment or gas activation; b) assembling the medical product; c) Setting up medical device for wet chemistry in which wet chemistry treatments follows a blood flow path through device; d) enhancing at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a strong oxidizing agent, such as ammonium persulfate; e) adding a positively charged spacer molecule to at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a cationic polymer, such as PEI; and f) covalently immobilizing heparin to at least the blood contacting surface with a wet chemistry treatment including heparin, preferably deaminated heparin.

A method of manufacturing a medical product having an engineered heparin bioactive matrix for clinical application on a blood contacting surface comprises: a) activating a blood contacting surface of at least one component of a medical device via one of plasma treatment or gas activation; b) assembling the medical product; c) Setting up medical device for wet chemistry in which wet chemistry treatments follows a blood flow path through device; d) enhancing at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a strong oxidizing agent, such as ammonium persulfate; e) adding a positively charged spacer molecule to at least the blood contacting surface with a wet chemistry treatment including an aqueous solution having a cationic polymer, such as PEI; and f) covalently immobilizing heparin to at least the blood contacting surface with a wet chemistry treatment including heparin, preferably deaminated heparin.